HER-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a Mexican Population of locally advanced breast cancer patients

By Muñoz-Gonzalez David   Zeichner-Gancz Isabel   Candelaria Myrna   Ramirez-Ugalde Maria   Perez-Sanchez Manuel   Cervantes-Vazquez Guadalupe   Cantu-de Leon David   Mora-Tizcareño Arcelia   Leonor-Ortíz Julio  

Medical Oncology, Vol. 22, Iss. 1, 2005-03 ,pp. : 23-28

Humana Press, Inc

Access to resources Recommend Favorite

HER2 as a prognostic and predictive marker for breast cancer

By Cooke T.   Reeves J.   Lanigan A.   Stanton P.  

Annals of Oncology, Vol. 12, Iss. 12, 2001-12 ,pp. : 23-28

Springer Publishing Company

Access to resources Recommend Favorite

Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer

By Köstler Wolfgang J.   Zielinski Christoph C.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 73-84

Springer Publishing Company

Access to resources Recommend Favorite

Prognostic and Predictive Impact of the HER-2/ neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer

By Müller Volkmar   Witzel Isabell   Lück Hans   Köhler Günter   Minckwitz Gunther   Möbus Volker   Sattler Daniel   Wilczak Waldemar   Löning Thomas   Jänicke Fritz   Pantel Klaus   Thomssen Christoph  

Breast Cancer Research and Treatment, Vol. 86, Iss. 1, 2004-07 ,pp. : 9-18

Springer Publishing Company

Access to resources Recommend Favorite

Prevalence of germline TP53 mutations in HER2+ breast cancer patients

By Rath Michelle  

Breast Cancer Research and Treatment, Vol. 139, Iss. 1, 2013-05 ,pp. : 193-198

Springer Publishing Company

Access to resources Recommend Favorite